Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib for NSCLC in Patients with HIV
NCT02134886Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Incidence of toxicities evaluated with NCI CTCAE v4.0 up to 30 days and Maximum Tolerated Dose at 28 days. Started Jul 2014; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02134886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134886.